Kura Oncology, Inc. (NASDAQ:KURA) Given Average Recommendation of "Moderate Buy" by Analysts

Shares of Kura Oncology, Inc. (NASDAQ:KURA - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the twelve analysts that are currently covering the company, Marketbeat reports. Three analysts have rated the stock with a hold recommendation, eight have given a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $27.13.

Several equities research analysts have recently issued reports on KURA shares. StockNews.com lowered shares of Kura Oncology from a "hold" rating to a "sell" rating in a report on Wednesday, November 20th. Jefferies Financial Group lowered their target price on shares of Kura Oncology from $32.00 to $28.00 and set a "buy" rating for the company in a report on Thursday, November 21st. Bank of America lowered their target price on shares of Kura Oncology from $36.00 to $29.00 and set a "buy" rating for the company in a report on Friday, November 22nd. TD Cowen restated a "buy" rating on shares of Kura Oncology in a report on Thursday, November 21st. Finally, BTIG Research lowered shares of Kura Oncology from a "buy" rating to a "neutral" rating in a report on Thursday, February 6th.

Insider Buying and Selling at Kura Oncology

In related news, SVP Thomas James Doyle sold 4,949 shares of the firm's stock in a transaction on Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total transaction of $38,948.63. Following the transaction, the senior vice president now directly owns 88,193 shares in the company, valued at $694,078.91. This trade represents a 5.31 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Mollie Leoni sold 4,963 shares of the firm's stock in a transaction on Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total value of $39,058.81. Following the transaction, the insider now owns 88,253 shares in the company, valued at $694,551.11. This trade represents a 5.32 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 11,729 shares of company stock valued at $92,307 over the last 90 days. 5.50% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the company. Suvretta Capital Management LLC boosted its position in Kura Oncology by 8.2% during the 3rd quarter. Suvretta Capital Management LLC now owns 7,652,782 shares of the company's stock worth $149,535,000 after acquiring an additional 583,155 shares during the period. Vanguard Group Inc. boosted its position in Kura Oncology by 14.6% during the 4th quarter. Vanguard Group Inc. now owns 4,818,898 shares of the company's stock worth $41,973,000 after acquiring an additional 615,211 shares during the period. RA Capital Management L.P. acquired a new stake in Kura Oncology during the 4th quarter worth about $38,769,000. Millennium Management LLC boosted its position in Kura Oncology by 180.1% during the 4th quarter. Millennium Management LLC now owns 2,367,148 shares of the company's stock worth $20,618,000 after acquiring an additional 1,521,954 shares during the period. Finally, Geode Capital Management LLC boosted its position in Kura Oncology by 2.4% during the 3rd quarter. Geode Capital Management LLC now owns 1,780,509 shares of the company's stock worth $34,798,000 after acquiring an additional 41,535 shares during the period.

Kura Oncology Stock Up 1.2 %

KURA traded up $0.10 during midday trading on Tuesday, reaching $8.25. The company's stock had a trading volume of 971,849 shares, compared to its average volume of 1,683,910. The firm has a market capitalization of $641.21 million, a price-to-earnings ratio of -3.49 and a beta of 0.78. The company has a current ratio of 11.47, a quick ratio of 11.47 and a debt-to-equity ratio of 0.02. Kura Oncology has a 1 year low of $6.98 and a 1 year high of $24.17. The stock's 50-day moving average is $8.32 and its 200-day moving average is $14.26.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.